17 Result(s)

Article

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia

We investigated the prognostic impact of minimal residual disease (MRD) monitoring in acute myeloid leukemia patients harboring DNA methyltransferase 3A-R882H/-R882C mutations (DNMT3A^mut). MRD was determined by r...

V I Gaidzik, D Weber, P Paschka, A Kaumanns, S Krieger, A Corbacioglu, J Krönke… in Leukemia (2018)

Article

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure

We evaluated the impact of salvage regimens and allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) with induction failure. Between 1993 and 2009, 3324 patients with newly ...

M Wattad, D Weber, K Döhner, J Krauter, V I Gaidzik, P Paschka, M Heuser… in Leukemia (2017)

Article

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group

N Jahn, M Agrawal, L Bullinger, D Weber, A Corbacioglu, V I Gaidzik… in Leukemia (2017)

Article

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features

We evaluated the frequency, genetic architecture, clinico-pathologic features and prognostic impact of RUNX1 mutations in 2439 adult patients with newly-diagnosed acute myeloid leukemia (AML). RUNX1 mutations wer...

V I Gaidzik, V Teleanu, E Papaemmanuil, D Weber, P Paschka, J Hahn… in Leukemia (2016)

Article

Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients

U Platzbecker, H K Al-Ali, N Gattermann, D Haase, V Janzen, J Krauter, K Götze… in Leukemia (2014)

Article

Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells

Ineffective hematopoiesis is a major characteristic of myelodysplastic syndromes (MDS) causing relevant morbidity and mortality. Mesenchymal stromal cells (MSC) have been shown to physiologically support hemat...

S Geyh, S Öz, R-P Cadeddu, J Fröbel, B Brückner, A Kündgen, R Fenk, I Bruns… in Leukemia (2013)

Article

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

Myelodysplastic syndromes (MDS) with del(5q) are considered to have a benign course of the disease. In order to address the issue of the propensity of those patients to progress to acute myeloid leukemia (AML)...

U Germing, M Lauseker, B Hildebrandt, A Symeonidis, J Cermak, P Fenaux… in Leukemia (2012)

Article

Myelodysplastische Syndrome

Myelodysplastische Syndrome (MDS) sind erworbene Knochenmarkerkrankungen des vornehmlich älteren Menschen, die durch Reifungs- und Funktionsstörungen hämatopoetischer Stammzellen, ineffektive Hämatopoese und e...

PD Dr. U. Germing, A. Kündgen, C. Strupp, M. Aivado… in best practice onkologie (2006)

Article

Primary pancreatic lymphoma—a rare cause of cholestasis leading to surgical treatment

I. Alldinger, M. Peiper, R. Diallo, L. Poll, A. Kündgen, U. Germing… in Annals of Hematology (2006)

Article

Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine

Intravenous low-dose 5-aza-2′-deoxycytidine (decitabine) in patients with advanced myelodysplastic syndrome (MDS) yields an approximately 50% overall response rate, including 20–25% complete remission. Decitab...

J. A. Pitako, P. S. Haas, J. Van den Bosch, H. Müller-Berndorff… in Annals of Hematology (2005)

Article

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)

The international prognostic scoring system (IPSS) is considered the gold standard for risk assessment in primary myelodysplastic syndromes (MDS). This score includes several prognostic factors except serum la...

U Germing, B Hildebrandt, M Pfeilstöcker, T Nösslinger, P Valent, C Fonatsch… in Leukemia (2005)